Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

NSCLC: Update Bulletin #3 [May 2018]

Product Code:
596200957
Publication Date:
May 2018
Format:
PDF
Price:
£910

This edition presents key opinion leader (KOL) views on recent developments in the non-small cell lung cancer (NSCLC) market. Topics covered include: the release of positive overall survival (OS) data from the KEYNOTE-189 trial of Merck & Co.’s Keytruda (pembrolizumab) in combination with chemotherapy, for the first-line treatment of metastatic nonsquamous NSCLC; the KEYNOTE-042 trial of first-line Keytruda as a monotherapy in locally advanced or metastatic NSCLC met its primary endpoint of OS in patients who are PD-L1 positive; progression-free survival (PFS) data were presented at the American Association for Cancer Research (AACR) from the Phase III CheckMate-227 trial evaluating the combination of Bristol-Myers Squibb’s (BMS) Opdivo (nivolumab) plus Yervoy (ipilimumab) in the first-line treatment of advanced NSCLC; the Phase III IMpower131 trial of Roche’s Tecentriq (atezolizumab) plus chemotherapy in the first-line treatment of squamous NSCLC met its PFS primary endpoint; the Phase III IMpower150 trial of Tecentriq in combination with Avastin (bevacizumab) and chemotherapy met its co-primary endpoint of extending OS in the first-line treatment of advanced nonsquamous NSCLC.    

Business Questions:

  • How do KOLs view the OS findings from the KEYNOTE-189 trial of Merck & Co.’s Keytruda in combination with chemotherapy?
  • How will the OS data from the KEYNOTE-189 trial impact treatment practice?
  • Will upfront PD-L1 testing continue to be standard practice in light of the benefit seen across the PD-L1 expression spectrum in KEYNOTE-189?
  • Will the adverse events associated with Keytruda plus pemetrexed and cisplatin or carboplatin limit its use?
  • How will the OS benefit seen in the KEYNOTE-042 trial impact the use of first-line Keytruda as a monotherapy?
  • How convinced are KOLs by the PFS data presented at AACR from the CheckMate-227 study of Opdivo plus Yervoy?
  • How is Opdivo/Yervoy’s tolerability profile perceived by KOLs and could it restrict the use of this combination as a first-line therapy?
  • What expectations do KOLs hold for the role of Tecentriq in combination with Avastin and chemotherapy in the first-line treatment of metastatic nonsquamous NSCLC?
  • How do KOLs interpret the news that the Phase III IMpower131 trial of Tecentriq plus chemotherapy met its co-primary endpoint of PFS in the first-line treatment of squamous cell carcinoma?






customer.service@firstwordpharma.com

All Contents Copyright © 2018 Doctor's Guide Publishing Limited All Rights Reserved